Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice.

Blood - 25 Nov 2010

Gorantla Sivahari P, Dechow Tobias N, Grundler Rebekka, Illert Anna Lena, Zum Büschenfelde Christian Meyer, Kremer Marcus, Peschel Christian, Duyster Justus

Abstract excerpt

The oncogenic JAK2V617F mutation is found in myeloproliferative neoplasms (MPNs) and is believed to be critical for leukemogenesis. Here we show that JAK2V617F requires an intact SH2 domain for constitutive activation of downstream signaling pathways. In addition, there is a strict requirement of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Cell Proliferation
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myeloproliferative Disorders

Share to Phosphorylation

Share to src Homology Domains

Source

Identifiers

PMID: 20696946
DOI: 10.1182/blood-2009-07-236133

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20696946-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice.PMID 20696946Read ↗

JAK2 activation in myeloproliferative neoplasms: a potential role for heterodimeric receptors.Semantic proximity Read ↗

Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm.Semantic proximity Read ↗

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.Semantic proximity Read ↗

The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells.Semantic proximity Read ↗

Binding of SH2-B family members within a potential negative regulatory region maintains JAK2 in an active state.Semantic proximity Read ↗

SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling.Semantic proximity Read ↗

Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations.Semantic proximity Read ↗

Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2V617F-induced Murine Myeloproliferative Neoplasm.Semantic proximity Read ↗

Activation loop tyrosines allow the JAK2(V617F) mutant to attain hyperactivation.Semantic proximity Read ↗

Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR.Semantic proximity Read ↗

An Unusual Insertion in Jak2 Is Crucial for Kinase Activity and Differentially Affects Cytokine ResponsesSemantic proximity Read ↗

JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.